TLX
Telix Pharmaceuticals Limited
NASDAQ: TLX · HEALTHCARE · BIOTECHNOLOGY
$10.43
-0.10% today
Updated 2026-04-29
Market cap
$3.53B
P/E ratio
—
P/S ratio
4.40x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$6 – $19
Volume
0.3M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A4.8
Quality
C3.0
Profitability
D6.7
Valuation
B2/9
Piotroski F-Score
Weak
1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$21.52
+106.33%
12-Month target
$0.14
-98.66%
Intrinsic (DCF)
$10.18
Margin of safety
+31.93%
0 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 49.30% QoQ
+ 31.93% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.53 — distress zone
- Thin margins at -0.89%
- Negative free cash flow $-92.60M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $160.10M | $502.55M | $783.21M | $1.21B | $803.79M |
| Net income | $-104.08M | $5.21M | $49.92M | $-10.69M | $-7.25M |
| EPS | — | — | — | — | $-0.02 |
| Free cash flow | $-71.01M | $14.21M | $28.71M | $-82.80M | $-92.60M |
| Profit margin | -65.01% | 1.04% | 6.37% | -0.89% | -0.89% |
Peer comparison
Smart narrative
Telix Pharmaceuticals Limited trades at $10.43. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.53, it sits in the distress. TTM revenue stands at $803.79M. with profit margins at -0.89%. Our DCF model estimates intrinsic value at $10.18.
Frequently asked questions
What is Telix Pharmaceuticals Limited's stock price?
Telix Pharmaceuticals Limited (TLX) trades at $10.43.
Is Telix Pharmaceuticals Limited overvalued?
Smart Value Score 27/100 (Grade F, Strong Sell). DCF value $10.18.
What is the price target of Telix Pharmaceuticals Limited (TLX)?
The analyst target price is $21.52, representing +106.3% upside from the current price of $10.43.
What is the intrinsic value of Telix Pharmaceuticals Limited (TLX)?
Based on our DCF model, intrinsic value is $10.18, a +31.9% margin of safety versus $10.43.
What is Telix Pharmaceuticals Limited's revenue?
TTM revenue is $803.79M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
1.53 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.40x
ROE-1.86%
Beta0.61
50D MA$8.81
200D MA$9.62
Shares out0.34B
Float0.27B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—